Will "combined prevention" eliminate racial/ethnic disparities in HIV infection among persons who inject drugs in New York City?

Don Des Jarlais, Kamyar Arasteh, Courtney Mcknight, Jonathan Feelemyer, Holly Hagan, Hannah Cooper, Aimee Campbell, Susan Tross, David Perlman

Research output: Contribution to journalArticle

Abstract

It has not been determined whether implementation of combined prevention programming for persons who inject drugs reduce racial/ethnic disparities in HIV infection. We examine racial/ethnic disparities in New York City among persons who inject drugs after implementation of the New York City Condom Social Marketing Program in 2007. Quantitative interviews and HIV testing were conducted among persons who inject drugs entering Mount Sinai Beth Israel drug treatment (2007-2014). 703 persons who inject drugs who began injecting after implementation of large-scale syringe exchange were included in the analyses. Factors independently associated with being HIV seropositive were identified and a published model was used to estimate HIV infections due to sexual transmission. Overall HIV prevalence was 4%; Whites 1%, African-Americans 17%, and Hispanics 4%. Adjusted odds ratios were 21.0 (95% CI 5.7, 77.5) for African-Americans to Whites and 4.5 (95% CI 1.3, 16.3) for Hispanics to Whites. There was an overall significant trend towards reduced HIV prevalence over time (adjusted odd ratio = 0.7 per year, 95% confidence interval (0.6-0.8). An estimated 75% or more of the HIV infections were due to sexual transmission. Racial/ethnic disparities among persons who inject drugs were not significantly different from previous disparities. Reducing these persistent disparities may require new interventions (treatment as prevention, pre-exposure prophylaxis) for all racial/ethnic groups.

Original languageEnglish (US)
Article numbere0126180
JournalPLoS One
Volume10
Issue number5
DOIs
StatePublished - May 12 2015

Fingerprint

HIV infections
HIV Infections
drugs
HIV
Pharmaceutical Preparations
African Americans
odds ratio
Hispanic Americans
social marketing
Drug therapy
Syringes
Odds Ratio
Social Marketing
syringes
nationalities and ethnic groups
Israel
drug therapy
Condoms
Marketing
confidence interval

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Will "combined prevention" eliminate racial/ethnic disparities in HIV infection among persons who inject drugs in New York City? / Des Jarlais, Don; Arasteh, Kamyar; Mcknight, Courtney; Feelemyer, Jonathan; Hagan, Holly; Cooper, Hannah; Campbell, Aimee; Tross, Susan; Perlman, David.

In: PLoS One, Vol. 10, No. 5, e0126180, 12.05.2015.

Research output: Contribution to journalArticle

@article{004059872e634e57b2294262f1198388,
title = "Will {"}combined prevention{"} eliminate racial/ethnic disparities in HIV infection among persons who inject drugs in New York City?",
abstract = "It has not been determined whether implementation of combined prevention programming for persons who inject drugs reduce racial/ethnic disparities in HIV infection. We examine racial/ethnic disparities in New York City among persons who inject drugs after implementation of the New York City Condom Social Marketing Program in 2007. Quantitative interviews and HIV testing were conducted among persons who inject drugs entering Mount Sinai Beth Israel drug treatment (2007-2014). 703 persons who inject drugs who began injecting after implementation of large-scale syringe exchange were included in the analyses. Factors independently associated with being HIV seropositive were identified and a published model was used to estimate HIV infections due to sexual transmission. Overall HIV prevalence was 4{\%}; Whites 1{\%}, African-Americans 17{\%}, and Hispanics 4{\%}. Adjusted odds ratios were 21.0 (95{\%} CI 5.7, 77.5) for African-Americans to Whites and 4.5 (95{\%} CI 1.3, 16.3) for Hispanics to Whites. There was an overall significant trend towards reduced HIV prevalence over time (adjusted odd ratio = 0.7 per year, 95{\%} confidence interval (0.6-0.8). An estimated 75{\%} or more of the HIV infections were due to sexual transmission. Racial/ethnic disparities among persons who inject drugs were not significantly different from previous disparities. Reducing these persistent disparities may require new interventions (treatment as prevention, pre-exposure prophylaxis) for all racial/ethnic groups.",
author = "{Des Jarlais}, Don and Kamyar Arasteh and Courtney Mcknight and Jonathan Feelemyer and Holly Hagan and Hannah Cooper and Aimee Campbell and Susan Tross and David Perlman",
year = "2015",
month = "5",
day = "12",
doi = "10.1371/journal.pone.0126180",
language = "English (US)",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

TY - JOUR

T1 - Will "combined prevention" eliminate racial/ethnic disparities in HIV infection among persons who inject drugs in New York City?

AU - Des Jarlais, Don

AU - Arasteh, Kamyar

AU - Mcknight, Courtney

AU - Feelemyer, Jonathan

AU - Hagan, Holly

AU - Cooper, Hannah

AU - Campbell, Aimee

AU - Tross, Susan

AU - Perlman, David

PY - 2015/5/12

Y1 - 2015/5/12

N2 - It has not been determined whether implementation of combined prevention programming for persons who inject drugs reduce racial/ethnic disparities in HIV infection. We examine racial/ethnic disparities in New York City among persons who inject drugs after implementation of the New York City Condom Social Marketing Program in 2007. Quantitative interviews and HIV testing were conducted among persons who inject drugs entering Mount Sinai Beth Israel drug treatment (2007-2014). 703 persons who inject drugs who began injecting after implementation of large-scale syringe exchange were included in the analyses. Factors independently associated with being HIV seropositive were identified and a published model was used to estimate HIV infections due to sexual transmission. Overall HIV prevalence was 4%; Whites 1%, African-Americans 17%, and Hispanics 4%. Adjusted odds ratios were 21.0 (95% CI 5.7, 77.5) for African-Americans to Whites and 4.5 (95% CI 1.3, 16.3) for Hispanics to Whites. There was an overall significant trend towards reduced HIV prevalence over time (adjusted odd ratio = 0.7 per year, 95% confidence interval (0.6-0.8). An estimated 75% or more of the HIV infections were due to sexual transmission. Racial/ethnic disparities among persons who inject drugs were not significantly different from previous disparities. Reducing these persistent disparities may require new interventions (treatment as prevention, pre-exposure prophylaxis) for all racial/ethnic groups.

AB - It has not been determined whether implementation of combined prevention programming for persons who inject drugs reduce racial/ethnic disparities in HIV infection. We examine racial/ethnic disparities in New York City among persons who inject drugs after implementation of the New York City Condom Social Marketing Program in 2007. Quantitative interviews and HIV testing were conducted among persons who inject drugs entering Mount Sinai Beth Israel drug treatment (2007-2014). 703 persons who inject drugs who began injecting after implementation of large-scale syringe exchange were included in the analyses. Factors independently associated with being HIV seropositive were identified and a published model was used to estimate HIV infections due to sexual transmission. Overall HIV prevalence was 4%; Whites 1%, African-Americans 17%, and Hispanics 4%. Adjusted odds ratios were 21.0 (95% CI 5.7, 77.5) for African-Americans to Whites and 4.5 (95% CI 1.3, 16.3) for Hispanics to Whites. There was an overall significant trend towards reduced HIV prevalence over time (adjusted odd ratio = 0.7 per year, 95% confidence interval (0.6-0.8). An estimated 75% or more of the HIV infections were due to sexual transmission. Racial/ethnic disparities among persons who inject drugs were not significantly different from previous disparities. Reducing these persistent disparities may require new interventions (treatment as prevention, pre-exposure prophylaxis) for all racial/ethnic groups.

UR - http://www.scopus.com/inward/record.url?scp=84930666656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930666656&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0126180

DO - 10.1371/journal.pone.0126180

M3 - Article

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 5

M1 - e0126180

ER -